Sunday, November 15, 2026

Expanding the Covalent Warhead Toolbox: Discovery of the First Covalent PARG Inhibitors Using Bicyclo[1.1.0]butane-Based Warheads

Olivier Querolle  and Luca Iacovino  and Andreas Goutopoulos  and Tian Jin  and Zaixu Xu  and Marta Malattia  and Nicolas Bocquet  and Alena Freudenmann  and Marina Gysin  and Hanna Kok  and Jason Clochard  and Roxanne Lourman  and Anika Kuster  and Serena Bologna  and Irena Konstantinova  and Sotirios K. Sotiriou  and Thanos D. Halazonetis  and James Mills  and Ronen Gabizon  and Almog Nadir  and Nir London  and Tarig Bashir  and Frank T. Zenke  and Ulrich Lücking

ChemRxiv. 10 November 2026.

DOI: https://doi.org/10.26434/chemrxiv.15011922/v1

Poly(ADP-ribose) glycohydrolase (PARG) is the principal enzyme responsible for the degradation of poly(ADP-ribose) chains and has emerged as a promising therapeutic target in oncology within the DNA damage response (DDR) field. Although several reversible PARG inhibitors have recently entered clinical development, covalent inhibition of PARG has not previously been described. Herein, we report the discovery and optimization of the first covalent PARG inhibitors. Guided by structural analysis of the PARG catalytic domain, electrophilic warheads were incorporated into reversible quinazolinedione-based inhibitors to enable selective engagement of Cys872, a residue located within the catalytic pocket. While unsaturated ketone and hydrazide warheads enabled covalent inhibition of PARG, incorporation of a bicyclo[1.1.0]butane (BCB) hydrazide warhead led to the discovery of FORX-175, combining potent biochemical and cellular activity, reduced electrophile reactivity, and improved covalent-labeling selectivity. To the best of our knowledge, this work represents the first application of a BCB hydrazide warhead for selective covalent cysteine targeting. Building on these findings, a hybrid design strategy combining structural elements of the covalent quinazolinedione series with those of a reversible PARG inhibitor series led to the discovery of FORX-425, a covalent quinoline inhibitor bearing an underexplored BCB-carboxamide warhead. FORX-425 displayed potent biochemical inhibition, efficient covalent engagement, and nanomolar cellular activity in PARG-sensitive cancer cell lines. Collectively, these studies establish covalent inhibition as a viable strategy for PARG modulation, identify Cys872 as a tractable site for selective covalent targeting, and further demonstrate the potential of BCB-derived warheads for cysteine-directed drug discovery.

Expanding the Covalent Warhead Toolbox: Discovery of the First Covalent PARG Inhibitors Using Bicyclo[1.1.0]butane-Based Warheads

Olivier Querolle  and Luca Iacovino  and Andreas Goutopoulos  and Tian Jin  and Zaixu Xu  and Marta Malattia  and Nicolas Bocquet  and Alena...